Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges

Over the past decade, immunotherapy, especially cell-based immunotherapy, has provided new strategies for cancer therapy. Recent clinical studies demonstrated that adopting cell transfer of tumor-infiltrating lymphocytes (TILs) for advanced solid tumors showed good efficacy. TIL therapy is a type of...

Full description

Saved in:
Bibliographic Details
Published inCancers Vol. 14; no. 17; p. 4160
Main Authors Zhao, Yueshui, Deng, Jian, Rao, Shuangfeng, Guo, Sipeng, Shen, Jing, Du, Fukuan, Wu, Xu, Chen, Yu, Li, Mingxing, Chen, Meijuan, Li, Xiaobing, Li, Wanping, Gu, Li, Sun, Yuhong, Zhang, Zhuo, Wen, Qinglian, Xiao, Zhangang, Li, Jing
Format Journal Article
LanguageEnglish
Published Basel MDPI AG 27.08.2022
MDPI
Subjects
Antigens
Awards & honors
Breast cancer
Cancer
Care and treatment
Cervical cancer
Cholangiocarcinoma
Clinical trials
Colorectal cancer
Drug dosages
Health aspects
Human papillomavirus
Immunotherapy
Interleukin 2
Lymphocytes
Medical research
Melanoma
Metastasis
Microenvironments
Patients
Response rates
Review
Solid tumors
Toxicity
Tumor cells
Tumor-infiltrating lymphocytes
Tumors
China
Online AccessGet full text

Cover

More Information
Summary:Over the past decade, immunotherapy, especially cell-based immunotherapy, has provided new strategies for cancer therapy. Recent clinical studies demonstrated that adopting cell transfer of tumor-infiltrating lymphocytes (TILs) for advanced solid tumors showed good efficacy. TIL therapy is a type of cell-based immunotherapy using the patient’s own immune cells from the microenvironment of the solid tumor to kill tumor cells. In this review, we provide a comprehensive summary of the current strategies and challenges in TIL isolation and generation. Moreover, the current clinical experience of TIL therapy is summarized and discussed, with an emphasis on lymphodepletion regimen, the use of interleukin-2, and related toxicity. Furthermore, we highlight the clinical trials where TIL therapy is used independently and in combination with other types of therapy for solid cancers. Finally, the limitations, future potential, and directions of TIL therapy for solid tumor treatment are also discussed.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
These authors contributed equally to this work.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers14174160